Back to Search
DANIEL SALAZAR, MD
MD
Internal Medicine Physician
NPI: 1710148192Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
4301099807(MI)
Research & Publications (20)
Blastomycosis: case report investigating a persistent pulmonary lesion in an immunocompromised patient.
PMID 19678501·J Ky Med Assoc·2009
5-case
Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38.
PMID 19546250·J Clin Pharmacol·2009
8-other
Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects.
PMID 19530977·Curr Med Res Opin·2009
3-trial
Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination.
PMID 18974285·J Clin Pharmacol·2008
8-other
Maternal glutaric acidemia, type I identified by newborn screening.
PMID 18304851·Mol Genet Metab·2008
5-case
Model-based development of a PPARgamma agonist, rivoglitazone, to aid dose selection and optimize clinical trial designs.
PMID 18936283·J Clin Pharmacol·2008
3-trial
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.
PMID 19023649·J Pharmacokinet Pharmacodyn·2008
2-rct
Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects.
PMID 19025429·Pharmacotherapy·2008
2-rct
Pain relief model for a COX-2 inhibitor in patients with postoperative dental pain.
PMID 18522627·Br J Clin Pharmacol·2008
4-observational
Evaluation of population pharmacokinetics and exposure-response relationship with coadministration of amlodipine besylate and olmesartan medoxomil.
PMID 18490496·J Clin Pharmacol·2008
3-trial
Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans.
PMID 18094219·J Clin Pharmacol·2008
3-trial
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
PMID 18303127·J Clin Pharmacol·2008
2-rct
The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.
PMID 18278193·Thromb Haemost·2008
4-observational
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
PMID 18217157·Thromb Haemost·2008
4-observational
Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
PMID 18786302·Curr Med Res Opin·2008
2-rct
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.
PMID 18569863·Platelets·2008
2-rct
Pharmacokinetics of aripiprazole and concomitant carbamazepine.
PMID 17502775·J Clin Psychopharmacol·2007
3-trial
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
PMID 17900275·J Thromb Haemost·2007
8-other
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
PMID 18030066·J Cardiovasc Pharmacol·2007
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 39 OAKLAND AVE
BLOOMFIELD, NJ 07003 - Phone
- (347) 604-3971
Quick Facts
- NPI
- 1710148192
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile